All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 8 February 2018, long term safety and efficacy study results of ibrutinib use in patients with chronic lymphocytic leukemia (CLL) were published online in Blood. The study by Susan O’Brien, University of Texas MD Anderson Cancer Center, and the University of California, and colleagues, highlighted outcomes in relapsed/refractory (R/R) and treatment-naïve (TN) patients after a follow-up of 5 years.
The authors concluded that ibrutinib as a single agent showed long term efficacy and durable responses with an acceptable safety profile in patients with CLL. Similar results were also reflected in another long term follow-up study with ibrutinib in CLL patients by Inhye Ahn et al. The study authors found that ibrutinib also demonstrated durable responses after 5 years in TN and R/R CLL patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox